Australia	NNP	O
has	VBZ	B
a	DT	I
slightly	RB	O
different	JJ	B
pregnancy	NN	O
category	NN	O
system	NN	O
from	IN	O
the	DT	B
United	NNP	O
States	NNP	O
-	HYPH	B
notably	RB	O
the	DT	B
subdivision	NN	O
of	IN	B
Category	NNP	O
B.	NNP	O

The	DT	B
system	NN	O
,	,	B
as	IN	O
outlined	VBN	O
below	IN	O
,	,	B
was	VBD	I
established	VBN	O
by	IN	O
the	DT	B
Congenital	NNP	O
Abnormalities	NNPS	O
Sub	NNP	O
-	HYPH	B
committee	NN	O
of	IN	B
the	DT	I
Australian	NNP	O
Drug	NNP	O
Evaluation	NNP	O
Committee	NNP	O
(	-LRB-	O
ADEC	NNP	O
)	-RRB-	O
.	.	O

ADEC	NNP	O
Pregnancy	NNP	O
Categories	NNP	O
(	-LRB-	O
Australia	NNP	O
)	-RRB-	O

'	``	B
Pregnancy	NN	O
Category	NNP	O
A	NNP	B
'	''	I

Drugs	NNS	O
which	WDT	B
have	VBP	I
been	VBN	B
taken	VBN	O
by	IN	O
a	DT	B
large	JJ	O
number	NN	B
of	IN	I
pregnant	JJ	O
women	NNS	O
and	CC	B
women	NNS	O
of	IN	B
childbearing	NN	O
age	NN	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	B
frequency	NN	O
of	IN	B
malformations	NNS	O
or	CC	B
other	JJ	I
direct	JJ	O
or	CC	B
indirect	JJ	O
harmful	JJ	O
effects	NNS	O
on	IN	O
the	DT	B
fetus	NN	O
having	VBG	O
been	VBN	B
observed	VBN	I
.	.	O

'	``	B
Pregnancy	NN	O
Category	NN	O
B1	NN	O
'	''	B

Drugs	NNS	O
which	WDT	B
have	VBP	I
been	VBN	B
taken	VBN	O
by	IN	O
only	RB	O
a	DT	B
limited	JJ	O
number	NN	B
of	IN	I
pregnant	JJ	O
women	NNS	O
and	CC	B
women	NNS	O
of	IN	B
childbearing	VBG	O
age	NN	O
,	,	B
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	B
frequency	NN	O
of	IN	B
malformation	NN	O
or	CC	B
other	JJ	I
direct	JJ	O
or	CC	B
indirect	JJ	O
harmful	JJ	O
effects	NNS	O
on	IN	O
the	DT	B
human	JJ	O
fetus	NN	O
having	VBG	O
been	VBN	B
observed	VBN	I
.	.	O

Studies	NNS	O
in	IN	O
animals	NNS	O
have	VBP	B
not	RB	I
shown	VBN	O
evidence	NN	B
of	IN	I
an	DT	O
increased	VBN	O
occurrence	NN	O
of	IN	B
fetal	JJ	O
damage	NN	O
.	.	O

'	``	B
Pregnancy	NN	O
Category	NN	O
B2	NN	O
'	''	B

Drugs	NNS	O
which	WDT	B
have	VBP	I
been	VBN	B
taken	VBN	O
by	IN	O
only	RB	O
a	DT	B
limited	JJ	O
number	NN	B
of	IN	I
pregnant	JJ	O
women	NNS	O
and	CC	B
women	NNS	O
of	IN	B
childbearing	VBG	O
age	NN	O
,	,	B
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	B
frequency	NN	O
of	IN	B
malformation	NN	O
or	CC	B
other	JJ	I
direct	JJ	O
or	CC	B
indirect	JJ	O
harmful	JJ	O
effects	NNS	O
on	IN	O
the	DT	B
human	JJ	O
fetus	NN	O
having	VBG	O
been	VBN	B
observed	VBN	I
.	.	O

Studies	NNS	O
in	IN	O
animals	NNS	O
are	VBP	B
inadequate	JJ	O
or	CC	B
may	MD	I
be	VB	B
lacking	VBG	O
,	,	B
but	CC	O
available	JJ	O
data	NNS	O
show	VBP	O
no	DT	O
evidence	NN	B
of	IN	I
an	DT	O
increased	VBN	O
occurrence	NN	O
of	IN	B
fetal	JJ	O
damage	NN	O
.	.	O

'	``	B
Pregnancy	NN	O
Category	NN	O
B3	NN	O
'	''	B

Drugs	NNS	O
which	WDT	B
have	VBP	I
been	VBN	B
taken	VBN	O
by	IN	O
only	RB	O
a	DT	B
limited	JJ	O
number	NN	B
of	IN	I
pregnant	JJ	O
women	NNS	O
and	CC	B
women	NNS	O
of	IN	B
childbearing	VBG	O
age	NN	O
,	,	B
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	B
frequency	NN	O
of	IN	B
malformation	NN	O
or	CC	B
other	JJ	I
direct	JJ	O
or	CC	B
indirect	JJ	O
harmful	JJ	O
effects	NNS	O
on	IN	O
the	DT	B
human	JJ	O
fetus	NN	O
having	VBG	O
been	VBN	B
observed	VBN	I
.	.	O

Studies	NNS	O
in	IN	O
animals	NNS	O
have	VBP	B
shown	VBN	O
evidence	NN	B
of	IN	I
an	DT	O
increased	VBN	O
occurrence	NN	O
of	IN	B
fetal	JJ	O
damage	NN	O
,	,	B
the	DT	I
significance	NN	O
of	IN	B
which	WDT	I
is	VBZ	B
considered	VBN	I
uncertain	JJ	O
in	IN	O
humans	NNS	O
.	.	O

'	``	B
Pregnancy	NN	O
Category	NN	O
C	NNP	O

'	``	B
Drugs	NNS	O
which	WDT	B
,	,	I
owing	VBG	O
to	IN	B
their	PRP$	O
pharmaceutical	JJ	O
effects	NNS	O
,	,	B
have	VBP	I
caused	VBN	O
or	CC	B
may	MD	I
be	VB	B
suspected	VBN	O
of	IN	B
causing	VBG	O
,	,	B
harmful	JJ	O
effects	NNS	O
on	IN	O
the	DT	B
human	JJ	O
fetus	NN	O
or	CC	B
neonate	NN	O
without	IN	O
causing	VBG	O
malformations	NNS	O
.	.	O

These	DT	O
effects	NNS	O
may	MD	B
be	VB	I
reversible	JJ	O
.	.	O

'	``	B
Pregnancy	NN	O
Category	NN	O
D	NN	O
'	''	B

Drugs	NNS	O
which	WDT	B
have	VBP	I
caused	VBN	O
,	,	B
are	VBP	I
suspected	VBN	O
to	TO	B
have	VB	I
caused	VBN	O
or	CC	B
may	MD	I
be	VB	B
expected	VBN	I
to	TO	B
cause	VB	O
,	,	B
an	DT	O
increased	VBN	O
incidence	NN	O
of	IN	B
human	JJ	O
fetal	JJ	O
malformations	NNS	O
or	CC	B
irreversible	JJ	O
damage	NN	O
.	.	O

These	DT	O
drugs	NNS	O
may	MD	B
also	RB	I
have	VB	B
adverse	JJ	O
pharmacological	JJ	O
effects	NNS	O
.	.	O
'	''	B

